Difference between revisions of "Plinabulin (NPI-2358)"
Jump to navigation
Jump to search
m |
m |
||
Line 14: | Line 14: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
− | [[Category:Non-small cell lung cancer medications]] | + | [[Category:Non-small cell lung cancer medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] |
Latest revision as of 02:18, 29 April 2022
Mechanism of action
From the NCI Drug Dictionary: An orally active diketopiperazine derivative with potential antineoplastic activity. Plinabulin selectively binds to the colchicine-binding site of tubulin, thereby interrupting equilibrium of microtubule dynamics; mitotic spindle assembly is disrupted, resulting in cell cycle arrest at the M phase and blockage of cell division in tumor cells. In addition, this agent induces tubulin depolymerization in vascular endothelial cells, resulting in the disruption of tumor blood vessel architecture and a selective collapse of tumor vasculature.
Preliminary data
Non-small cell lung cancer
- Abstract: Ramon W. Mohanlal, Ken LLoyd, Lan Huang, Lyudmila Bazhenova. Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC. J Clin Oncol 35, 2017 (suppl 7S; abstract 139) link to abstract
Also known as
- Code name: NPI-2358